HEALTHCARE
DRUG DELIVERY TECHNOLOGY MARKET FORECAST TO 2020
DRUG DELIVERY TECHNOLOGY MARKET - FORECAST TO 2020 Route Of Administration (Oral {Solid}, Pulmonary {Nebulizer}, Injectable {Device}, Ocular {Liquid}, Nasal {Drop}, Topical {Solid}, Implantable {Active}, Transmucosal {Oral}), End User (Hospital, ASC, Home Care)
REPORT OVERVIEW 1.1
OBJECTIVES OF THE STUDY •
To define, describe, and forecast the drug delivery technology market on the basis of route of administration and end user
•
To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
•
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
•
To forecast the size of the market segments with respect to four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW)2
•
To strategically profile the key players and comprehensively analyze their market shares and core competencies3
•
To track and analyze competitive developments such as joint ventures, mergers and acquisitions, new product developments, expansions, and research and development activities in the drug delivery technology market
sales@marketsandmarkets.com
www.marketsandmarkets.com
1
INTRODUCTION
1.2
MARKET DEFINITION
•
Drug delivery is a method or process of administration of a pharmaceutical drug to safely attain its desired therapeutic effect. Advancements in drug delivery offer several benefits such as ease of use, convenience, and patient compliance. Drug developers are focusing on suitable delivery and packaging options for increasing efficiency of the drug and proposing improved patient compliance. With technological advancements, there is reduction in drug wastage and convenience of drug administration at home.
1.3
MARKET SCOPE
1.3.1 MARKETS COVERED •
The research report categorizes the drug delivery technology market into the following segments: •
•
*The other end users segment includes academic and research institutions and other healthcare providers.
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
2
INTRODUCTION
•
Drug Delivery Technology Market, by Route of Administration •
Oral • Solid • Tablets • Capsules • Powders • Pills • Liquid • Solution • Syrups • Semi-solid • Gels • Emulsions • Elixir
•
Pulmonary • Metered Dose Inhalers • Dry Powder Inhalers • Nebulizers • Jet • Ultrasonic • Soft Mist
•
Injectables • Formulations • Novel Drug Delivery Formulations • Conventional Drug Delivery Formulations • Long-acting Injection Formulations • Devices • Conventional Injectables • By Material • Glass • Plastic
sales@marketsandmarkets.com
www.marketsandmarkets.com
3
INTRODUCTION
• By Product • Fillable Syringes • Prefilled Syringes • By Usability • Reusable • Disposable • Self-injections • Needle-free Injectors • Auto Injectors • Pen Injectors • Wearable Injectors • Other Devices •
Ocular • Liquid • Eye Drops • Liquid Sprays • Semi-solid • Gels • Ointments • Ocular Devices • Contact Lenses • Ocular Inserts
•
Nasal • Drops • Sprays • Powders • Gels
•
Topical • Liquid • Solutions • Suspensions
sales@marketsandmarkets.com
www.marketsandmarkets.com
4
INTRODUCTION
• Semi-solid • Creams • Gels • Ointments • Paste • Lotions • Solid • Suppositories • Powder • Transdermal • Patches • Gels •
Implantable • Active Implantable Drug Delivery • Passive Implantable Drug Delivery
•
Transmucosal • Oral • Buccal • Sublingual • Others • Rectal • Vaginal
•
•
Drug Delivery Technology Market, by End User •
Hospitals
•
Homecare Settings
•
ASCs/Clinics
•
Diagnostic Centers
•
Other End Users
Drug Delivery Technology Market, by Region •
North America
•
U.S.
•
Canada
•
Europe
•
Asia
•
Rest of the World (RoW)
sales@marketsandmarkets.com
www.marketsandmarkets.com
5
INTRODUCTION
1.3.2 YEARS CONSIDERED FOR THE STUDY •
•
1.4 CURRENCY •
The currency used in this report is USD, with market size indicated in terms of USD Million. •
For companies reporting their revenues in USD, the revenues were picked from their annual reports
•
For companies that reported their revenues in other currencies, the average annual currency conversion rate was used for the particular year to convert the value to USD
1.5 LIMITATIONS
1.6
•
Some of the companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenues for those companies are not included in this report
•
The company developments not reported in the public domain are not included in the report
MARKET STAKEHOLDERS •
Drug Delivery Manufacturing Companies
•
Pharmaceutical and Medical Devices Manufacturing Companies
•
Healthcare Institutions (Hospitals and Outpatient Clinics)
•
Drug Delivery Distributors and Suppliers
•
Research Institutes
•
Health Insurance Payers
•
Market Research and Consulting Firms
sales@marketsandmarkets.com
www.marketsandmarkets.com
6
RESEARCH METHODOLOGY
•
This research study involved the usage of extensive secondary sources; directories; databases such as Hoovers, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies. Secondary research was mainly used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the drug delivery technology market. It was also used to obtain key information about the market classification and segmentation according to the industry trends, regional markets, and developments related to the market and technology perspectives. Primary sources were mainly several industry experts from core and related industries; and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry‘s value chain. In-depth interviews were conducted from various primary respondents which included key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects. The following figure shows the market research methodology applied in making this report. • FIGURE 1
RESEARCH DESIGN
•
•
•
•
• •
• •
•
•
• •
•
•
•
• •
•
•
In the secondary research process, various secondary sources were referred to identify and collect useful information for the study. These sources include annual reports, press releases, investor presentations of companies, white papers, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases.
sales@marketsandmarkets.com
www.marketsandmarkets.com
7
RESEARCH METHODOLOGY
•
Secondary research was mainly used to obtain key information about the industry’s value chain, market classification and segmentation according to the industry trends to the bottom-most level, geographical markets, and key developments from both market and technology-oriented perspectives.
•
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives. Primary sources from the demand side include expert researchers from research institutes, manufacturers and suppliers of drugs and devices, surgeons, and physicians.
•
After the complete market engineering (which includes calculations for market statistics, market breakdown, market size estimation, market forecasting, and data triangulation), extensive primary research was conducted to gather information and to verify and validate the critical numbers arrived at. Primary research was also conducted to identify the segmentation types and key market dynamics such as drivers, restraints, and opportunities.
•
In the complete market engineering process, both top-down and bottom-up approaches were extensively used along with several data triangulation methods to perform market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list key information/insights throughout the report.
2.1
MARKET SIZE ESTIMATION
•
Both, top-down and bottom-up approaches were used to estimate and validate sizes of the market and various other dependent submarkets of the drug delivery technology market. The research methodology used to estimate the market size includes the following details:
•
The key players in the market were identified through secondary research, and their market contributions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for the key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined by secondary sources and verified through primary sources. All possible parameters affecting the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to reach the final quantitative and qualitative data. This data is consolidated and added with detailed inputs and analyses from MarketsandMarkets and presented in this report.
•
The following figure shows an illustrative representation of the overall market size estimation process employed for this study. •
sales@marketsandmarkets.com
www.marketsandmarkets.com
8
RESEARCH METHODOLOGY
• FIGURE 2
MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
•
•
•
For estimating the size of the drug delivery technology market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each category (route of administration and end user). The drug delivery technology market size was derived by adding up the markets of all these categories. The total market derived through the bottom-up approach was again validated through secondary sources and primary interviews. • FIGURE 3
MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
•
•
•
The overall market size derived by the bottom-up approach was used in the top-down procedure to estimate the size of the drug delivery technology market through the percentage splits obtained from secondary and primary research for each product segment.
sales@marketsandmarkets.com
www.marketsandmarkets.com
9
RESEARCH METHODOLOGY
• FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
•
•
*Note: Others include sales managers, marketing managers, and product managers. Tiers of the companies are defined on the basis of their total revenue. As of 2013: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
2.2
MARKET BREAKDOWN AND DATA TRIANGULATION
•
After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. In order to complete the overall market engineering process and to arrive at the exact statistics for all the segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides. Along with this, the market was validated using both top-down and bottom-up approaches.
•
The following figure shows the market breakdown structure and the data triangulation methodology implemented in the market engineering process for making this report. •
sales@marketsandmarkets.com
www.marketsandmarkets.com
10
RESEARCH METHODOLOGY
• FIGURE 5
DATA TRIANGULATION METHODOLOGY
•
• • • • • •
•
•
•
• •
•
•
•
•
•
• •
• • • •
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
11
RESEARCH METHODOLOGY
2.3
KEY DATA FROM SECONDARY SOURCES • • • • • • •
• • • •
• • • • •
2.4
KEY DATA FROM PRIMARY SOURCES •
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
12
RESEARCH METHODOLOGY
2.5
ASSUMPTIONS FOR THE STUDY
•
• •
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
13
TABLE OF CONTENTS
1 INTRODUCTION.........................................................................................................................17 •
1.1
OBJECTIVES OF THE STUDY...........................................................................................................................................21
•
1.2
MARKET DEFINITION.......................................................................................................................................................21
•
1.3
MARKET SCOPE...............................................................................................................................................................22
•
1.3.1
MARKETS COVERED......................................................................................................................................22
•
1.3.2
YEARS CONSIDERED FOR THE STUDY.........................................................................................................26
•
1.4 CURRENCY......................................................................................................................................................................26
•
1.5 LIMITATIONS....................................................................................................................................................................26
•
1.6
2
MARKET STAKEHOLDERS................................................................................................................................................26
RESEARCH METHODOLOGY.....................................................................................................27 •
2.1
MARKET SIZE ESTIMATION.............................................................................................................................................28
•
2.2
MARKET BREAKDOWN AND DATA TRIANGULATION......................................................................................................30
•
2.3
KEY DATA FROM SECONDARY SOURCES.......................................................................................................................32
•
2.4
KEY DATA FROM PRIMARY SOURCES............................................................................................................................32
•
2.5
ASSUMPTIONS FOR THE STUDY....................................................................................................................................33
3
EXECUTIVE SUMMARY..............................................................................................................34
4
PREMIUM INSIGHTS.................................................................................................................38 •
4.1
DRUG DELIVERY TECHNOLOGY MARKET, BY TOPICAL DRUG DELIVERY.....................................................................38
•
4.2
DRUG DELIVERY TECHNOLOGY MARKET, BY END USER...............................................................................................39
•
4.3
SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM.................................................................40
•
4.4
DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION.................................................................41
•
4.5
GEOGRAPHIC SNAPSHOT OF THE DRUG DELIVERY TECHNOLOGY MARKET...............................................................42
5
MARKET OVERVIEW..................................................................................................................43 •
5.1 INTRODUCTION...............................................................................................................................................................44
•
5.2
MARKET SEGMENTATION................................................................................................................................................44
•
5.2.1
MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION.......................................................................44
•
5.2.2
MARKET SEGMENTATION, BY END USER.....................................................................................................45
•
5.2.3
MARKET SEGMENTATION, BY REGION.........................................................................................................45
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
14
TABLE OF CONTENTS
•
5.3
•
5.4 DRIVERS...........................................................................................................................................................................47
•
•
5.4.1
RISING PREVALENCE OF CHRONIC DISEASES.............................................................................................47
•
5.4.2
GROWTH IN THE BIOLOGICS MARKET.........................................................................................................48
•
5.4.3
NEW PRODUCT LAUNCHES..........................................................................................................................49
•
5.4.4
DRUG INNOVATION AND TECHNOLOGICAL ADVANCEMENTS....................................................................49
5.5 RESTRAINTS....................................................................................................................................................................51 •
•
•
6
MARKET DYNAMICS........................................................................................................................................................46
5.5.1
RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS RELATED TO DRUGS.............................................51
5.6 OPPORTUNITIES..............................................................................................................................................................52 •
5.6.1
SELF-ADMINISTRATION AND HOMECARE DRUG DELIVERY........................................................................52
•
5.6.2
RISING DEMAND FOR BIOSIMILARS AND GENERIC DRUGS.......................................................................52
•
5.6.2.1 BIOSIMILARS............................................................................................................................52
•
5.6.2.2
GENERIC DRUGS......................................................................................................................53
•
5.6.3
COLLABORATIONS AMONG COMPANIES.....................................................................................................53
•
5.6.4
FOCUS ON OVERCOMING UNMET MEDICAL NEEDS...................................................................................54
•
5.6.5
EMERGING MARKETS....................................................................................................................................55
5.7 CHALLENGES...................................................................................................................................................................56 •
5.7.1
PRODUCT RECALLS......................................................................................................................................56
•
5.7.2
PATENT EXPIRY AND PATENT CLIFF.............................................................................................................56
•
5.7.3
REGULATORY HURDLES AND PRICING PRESSURE......................................................................................57
DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION...........................58 •
6.1 INTRODUCTION...............................................................................................................................................................59
•
6.2 •
ORAL DRUG DELIVERY....................................................................................................................................................61 6.2.1
SOLID ORAL DRUGS......................................................................................................................................63
•
6.2.1.1 TABLETS...................................................................................................................................64
•
6.2.1.2 CAPSULES................................................................................................................................64
•
6.2.1.3 POWDERS.................................................................................................................................65
•
6.2.1.4 PILLS........................................................................................................................................66
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
15
TABLE OF CONTENTS
•
•
LIQUID ORAL DRUGS....................................................................................................................................66
•
6.2.2.1 SOLUTIONS..............................................................................................................................67
•
6.2.2.2 SYRUPS....................................................................................................................................68
•
•
6.2.2
6.2.3
SEMI-SOLID ORAL DRUGS............................................................................................................................69
•
6.2.3.1 GELS.........................................................................................................................................70
•
6.2.3.2 EMULSIONS.............................................................................................................................70
•
6.2.3.3 ELIXIRS.....................................................................................................................................71
6.3
PULMONARY DRUG DELIVERY.......................................................................................................................................72
•
6.3.1
METERED DOSE INHALERS...........................................................................................................................74
•
6.3.2
DRY POWDER INHALERS..............................................................................................................................75
•
6.3.3 NEBULIZERS..................................................................................................................................................76
•
6.3.3.1
JET NEBULIZERS......................................................................................................................77
•
6.3.3.2
ULTRASONIC NEBULIZERS.......................................................................................................77
•
6.3.3.3
SOFT MIST NEBULIZERS..........................................................................................................78
6.4 •
INJECTABLE DRUG DELIVERY.........................................................................................................................................79 6.4.1
INJECTABLE DRUG DELIVERY DEVICES.......................................................................................................81
•
6.4.1.1
CONVENTIONAL INJECTABLES................................................................................................82
•
6.4.1.2
BY MATERIAL...........................................................................................................................83
•
6.4.1.2.1 GLASS................................................................................................................84
•
6.4.1.2.2 PLASTIC.............................................................................................................85
•
6.4.1.3
BY PRODUCT............................................................................................................................86
•
6.4.1.3.1
FILLABLE SYRINGES..........................................................................................86
•
6.4.1.3.2
PREFILLED SYRINGES.......................................................................................87
•
6.4.1.4
BY USABILITY...........................................................................................................................88
•
6.4.1.4.1
REUSABLE SYRINGES........................................................................................88
•
6.4.1.4.2
DISPOSABLE SYRINGES....................................................................................89
•
6.4.1.5
SELF-INJECTION DEVICES.......................................................................................................89
•
6.4.1.6
NEEDLE-FREE INJECTORS.......................................................................................................91
•
6.4.1.7 AUTOINJECTORS......................................................................................................................92
•
6.4.1.8
PEN INJECTORS.......................................................................................................................92
•
6.4.1.9
WEARABLE INJECTORS............................................................................................................93
sales@marketsandmarkets.com
www.marketsandmarkets.com
16
TABLE OF CONTENTS
• •
•
INJECTABLE DRUG DELIVERY FORMULATIONS...........................................................................................95 6.4.2.1
CONVENTIONAL DRUG DELIVERY...........................................................................................96
•
6.4.2.2
NOVEL DRUG DELIVERY FORMULATIONS...............................................................................97
•
6.4.2.3
LONG-ACTING INJECTION FORMULATIONS...........................................................................98
6.5
OCULAR DRUG DELIVERY...............................................................................................................................................99 6.5.1
LIQUID OCULAR DRUG DELIVERY..............................................................................................................101
•
6.5.1.1
EYE DROPS.............................................................................................................................102
•
6.5.1.2
LIQUID SPRAYS......................................................................................................................102
•
6.5.2
SEMI-SOLID OCULAR DRUG DELIVERY......................................................................................................103
•
6.5.2.1 GELS.......................................................................................................................................104
•
6.5.2.2
•
•
6.4.2
OTHER DEVICES.......................................................................................................................94
•
•
•
6.4.1.10
6.5.3
EYE OINTMENTS....................................................................................................................105
OCULAR DEVICES.......................................................................................................................................105
•
6.5.3.1
CONTACT LENSES COATED WITH DRUGS............................................................................106
•
6.5.3.2
OCULAR INSERTS...................................................................................................................107
6.6
NASAL DRUG DELIVERY................................................................................................................................................108
•
6.6.1
NASAL DROPS.............................................................................................................................................110
•
6.6.2
NASAL SPRAYS...........................................................................................................................................110
•
6.6.3
NASAL POWDERS........................................................................................................................................111
•
6.6.4
NASAL GELS................................................................................................................................................111
6.7 •
TOPICAL DRUG DELIVERY.............................................................................................................................................112 6.7.1
LIQUID TOPICAL DRUG DELIVERY..............................................................................................................114
•
6.7.1.1 SOLUTIONS............................................................................................................................115
•
6.7.1.2 SUSPENSIONS.......................................................................................................................115
•
6.7.2
SEMI-SOLID TOPICAL DRUG DELIVERY.....................................................................................................116
•
6.7.2.1 CREAMS.................................................................................................................................117
•
6.7.2.2 GELS.......................................................................................................................................118
•
6.7.2.3 OINTMENTS............................................................................................................................118
•
6.7.2.4 PASTES...................................................................................................................................119
•
6.7.2.5 LOTIONS.................................................................................................................................120
sales@marketsandmarkets.com
www.marketsandmarkets.com
17
TABLE OF CONTENTS
•
•
6.7.3.1 SUPPOSITORIES.....................................................................................................................121
•
6.7.3.2 POWDERS...............................................................................................................................122 6.7.4
TRANSDERMAL DRUG DELIVERY...............................................................................................................122
•
6.7.4.1
TRANSDERMAL PATCHES......................................................................................................124
•
6.7.4.2
TRANSDERMAL GELS............................................................................................................124
6.8
IMPLANTABLE DRUG DELIVERY....................................................................................................................................125
•
6.8.1
ACTIVE IMPLANTABLE DRUG DELIVERY....................................................................................................127
•
6.8.2
PASSIVE IMPLANTABLE DRUG DELIVERY..................................................................................................128
6.9 •
TRANSMUCOSAL DRUG DELIVERY...............................................................................................................................129 6.9.1
ORAL TRANSMUCOSAL DRUG DELIVERY..................................................................................................131
•
6.9.1.1
BUCCAL DRUG DELIVERY......................................................................................................132
•
6.9.1.2
SUBLINGUAL DRUG DELIVERY..............................................................................................133
•
7
SOLID TOPICAL DRUG DELIVERY...............................................................................................................120
•
•
•
6.7.3
6.9.2
OTHER TRANSMUCOSAL DRUG DELIVERY................................................................................................134
•
6.9.2.1
RECTAL TRANSMUCOSAL DRUG DELIVERY..........................................................................135
•
6.9.2.2
VAGINAL TRANSMUCOSAL DRUG DELIVERY........................................................................135
DRUG DELIVERY TECHNOLOGY MARKET, BY END USER.......................................................137 •
7.1 INTRODUCTION.............................................................................................................................................................138
•
7.2 HOSPITALS....................................................................................................................................................................140
•
7.3
HOME CARE SETTINGS.................................................................................................................................................141
•
7.4
AMBULATORY SURGICAL CENTERS/CLINICS..............................................................................................................142
•
7.5
DIAGNOSTIC CENTERS..................................................................................................................................................143
•
7.6
OTHER END USERS........................................................................................................................................................144
8
DRUG DELIVERY TECHNOLOGY MARKET, BY REGION...........................................................145 •
8.1 INTRODUCTION.............................................................................................................................................................146
•
8.2
NORTH AMERICA...........................................................................................................................................................147
•
8.2.1 U.S...............................................................................................................................................................150
•
8.2.2 CANADA.......................................................................................................................................................152
•
8.3 EUROPE..........................................................................................................................................................................154
•
8.4 ASIA...............................................................................................................................................................................157
•
8.5
REST OF THE WORLD....................................................................................................................................................160
sales@marketsandmarkets.com
www.marketsandmarkets.com
18
TABLE OF CONTENTS
9
COMPETITIVE LANDSCAPE.....................................................................................................163 •
9.1 OVERVIEW......................................................................................................................................................................163
•
9.2
MARKET SHARE ANALYSIS...........................................................................................................................................164
•
9.3
COMPETITIVE SITUATIONS & TRENDS.........................................................................................................................165
10
•
9.3.1
NEW PRODUCT LAUNCHES & APPROVALS...............................................................................................167
•
9.3.2
PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS..........................................................................168
•
9.3.3 ACQUISITIONS.............................................................................................................................................169
•
9.3.4 EXPANSIONS...............................................................................................................................................170
COMPANY PROFILES...............................................................................................................171
• •
10.1 INTRODUCTION.............................................................................................................................................................171 (Company at a Glance, Recent Financials, Products & Services, Strategies & Insights, & Recent Developments)*
•
10.2
BAYER AG.......................................................................................................................................................................172
•
10.3
JOHNSON & JOHNSON SERVICES, INC........................................................................................................................175
•
10.4
NOVARTIS AG.................................................................................................................................................................182
•
10.5
PFIZER, INC....................................................................................................................................................................186
•
10.6
F. HOFFMANN-LA ROCHE LTD......................................................................................................................................196
•
10.7
3M COMPANY...............................................................................................................................................................204
•
10.8
ANTARES PHARMA, INC................................................................................................................................................207
•
10.9
GLAXOSMITHKLINE PLC...............................................................................................................................................209
•
10.10 MERCK & CO., INC........................................................................................................................................................212
•
10.11 SANOFI...........................................................................................................................................................................217
•
*Details on company at a glance, recent financials, products & services, strategies & insights, & recent developments might not be captured in case of unlisted companies.
11 APPENDIX................................................................................................................................222 •
11.1
INSIGHTS FROM INDUSTRY EXPERTS..........................................................................................................................222
•
11.2
DISCUSSION GUIDE......................................................................................................................................................223
•
11.3
OTHER DEVELOPMENTS, 2012–2015...........................................................................................................................226
•
11.4
AVAILABLE CUSTOMIZATIONS......................................................................................................................................240
•
11.5
RT: REAL-TIME MARKET INTELLIGENCE.......................................................................................................................240
•
11.6
RELATED REPORTS........................................................................................................................................................241
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
19
LIST OF TABLES
• TABLE 1
LIST OF BIOLOGICS EXPECTED TO GAIN U.S. REGULATORY APPROVAL IN 2015..........................................48
• TABLE 2
MAJOR PRODUCT LAUNCHES IN 2015............................................................................................................49
• TABLE 3
EXAMPLES OF TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY (2014–2015)..................................50
• TABLE 4
RISING PREVALENCE OF CHRONIC DISEASES IS DRIVING MARKET GROWTH..............................................50
• TABLE 5
RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS RELATED TO DRUGS ARE RESTRAINING MARKET GROWTH.....................................................................................................................51
• TABLE 6
RECENT COLLABORATIONS IN THE DRUG DELIVERY TECHNOLOGY MARKET, 2014–2015...........................54
• TABLE 7
EMERGING MARKETS EXPECTED TO OFFER SIGNIFICANT OPPORTUNITIES FOR MARKET PLAYERS...........................55
• TABLE 8
MAJOR PRODUCT RECALLS IN THE DRUG DELIVERY TECHNOLOGY MARKET, 2015....................................56
• TABLE 9
PATENT EXPIRY OF DRUGS, 2014–2015...........................................................................................................56
• TABLE 10
PRODUCT RECALLS POSE A SIGNIFICANT CHALLENGE FOR MARKET GROWTH..........................................57
• TABLE 11
DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)................................................................................................................................60
• TABLE 12
DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...............................60
• TABLE 13
ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION).........................62
• TABLE 14
ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).....................62
• TABLE 15
ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS, BY DOSAGE FORM, 2013–2020 (USD BILLION)...............................................................................................63
• TABLE 16
ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLID DRUGS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................63
• TABLE 17
SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR TABLETS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................64
• TABLE 18
SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR CAPSULES, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................65
• TABLE 19
SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR POWDERS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................65
• TABLE 20
SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR PILLS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................66
• TABLE 21
LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)................................................................................................................................66
• TABLE 22
LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................67
• TABLE 23
LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SOLUTIONS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................68
sales@marketsandmarkets.com
www.marketsandmarkets.com
20
LIST OF TABLES
• TABLE 24
LIQUID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR SYRUPS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................68
• TABLE 25
SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)................................................................................................................................69
• TABLE 26
SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)................................................................................................................................69
• TABLE 27
SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR GELS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................70
• TABLE 28
SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EMULSIONS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................71
• TABLE 29
SEMI-SOLID ORAL DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR ELIXIRS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................71
• TABLE 30
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)................................................................................................................................73
• TABLE 31
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)........................73
• TABLE 32
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR METERED DOSE INHALERS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................74
• TABLE 33
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR DRY POWDER INHALERS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................75
• TABLE 34
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR NEBULIZERS, BY DOSAGE FORM, 2013–2020 (USD BILLION)...............................................................................................76
• TABLE 35
PULMONARY DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR NEBULIZERS, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................76
• TABLE 36
JET NEBULIZERS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).......................................................77
• TABLE 37
ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).......................................78
• TABLE 38
SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..........................................78
• TABLE 39
INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)................................................................................................................................80
• TABLE 40
INJECTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)................................................................................................................................81
• TABLE 41
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY TYPE, 2013–2020 (USD BILLION).......................81
• TABLE 42
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................82
• TABLE 43
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................83
sales@marketsandmarkets.com
www.marketsandmarkets.com
21
LIST OF TABLES
• TABLE 44
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY MATERIAL, 2013–2020 (USD BILLION).......................................................................................................83
• TABLE 45
CONVENTIONAL GLASS INJECTION DEVICES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................84
• TABLE 46
CONVENTIONAL PLASTIC INJECTION DEVICES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................85
• TABLE 47
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY PRODUCT, 2013–2020 (USD BILLION)........................................................................................................86
• TABLE 48
CONVENTIONAL FILLABLE SYRINGES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).....................86
• TABLE 49
CONVENTIONAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................87
• TABLE 50
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR CONVENTIONAL INJECTABLES, BY USABILITY, 2013–2020 (USD BILLION).......................................................................................................88
• TABLE 51
CONVENTIONAL REUSABLE SYRINGES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................88
• TABLE 52
CONVENTIONAL DISPOSABLE SYRINGES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...............89
• TABLE 53
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR SELF-INJECTION DEVICES, BY TYPE, 2013–2020 (USD BILLION)................................................................................................................90
• TABLE 54
INJECTABLE DRUG DELIVERY DEVICES MARKET SIZE FOR SELF-INJECTION DEVICES, BY REGION, 2013–2020 (USD BILLION)...........................................................................................................90
• TABLE 55
NEEDLE-FREE INJECTORS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)........................................91
• TABLE 56
AUTOINJECTORS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)......................................................92
• TABLE 57
PEN INJECTORS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)........................................................93
• TABLE 58
WEARABLE INJECTORS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)............................................94
• TABLE 59
OTHER DEVICES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).......................................................94
• TABLE 60
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2013–2020 (USD BILLION)...........................95
• TABLE 61
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).......................96
• TABLE 62
CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)................................................................................................................................96
• TABLE 63
NOVEL DRUG DELIVERY FORMULATIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...............97
• TABLE 64
LONG-ACTING INJECTION FORMULATIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)............................98
• TABLE 65
OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION).....................100
• TABLE 66
OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............100
• TABLE 67
LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................101
• TABLE 68
LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)....................101
sales@marketsandmarkets.com
www.marketsandmarkets.com
22
LIST OF TABLES
• TABLE 69
LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EYE DROPS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................102
• TABLE 70
LIQUID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR LIQUID SPRAYS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................103
• TABLE 71
SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................103
• TABLE 72
SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................104
• TABLE 73
SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR GELS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................104
• TABLE 74
SEMI-SOLID OCULAR DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR EYE OINTMENTS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................105
• TABLE 75
OCULAR DEVICES DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................105
• TABLE 76
OCULAR DEVICES DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................106
• TABLE 77
CONTACT LENS COATED WITH DRUGS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).................106
• TABLE 78
OCULAR INSERTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................................................107
• TABLE 79
NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION).....................109
• TABLE 80
NASAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).................109
• TABLE 81
NASAL DROPS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)........................................................110
• TABLE 82
NASAL SPRAYS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).......................................................110
• TABLE 83
NASAL POWDERS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................................................111
• TABLE 84
NASAL GELS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...........................................................111
• TABLE 85
TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)....................113
• TABLE 86
TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).............113
• TABLE 87
LIQUID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................114
• TABLE 88
LIQUID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)....................114
• TABLE 89
TOPICAL DRUG DELIVERY SOLUTIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).................115
• TABLE 90
TOPICAL DRUG DELIVERY SUSPENSIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)............116
• TABLE 91
SEMI-SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................116
sales@marketsandmarkets.com
www.marketsandmarkets.com
23
LIST OF TABLES
• TABLE 92
SEMI-SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................................................................................................117
• TABLE 93
TOPICAL DRUG DELIVERY CREAMS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)......................117
• TABLE 94
TOPICAL DRUG DELIVERY GELS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)............................118
• TABLE 95
TOPICAL DRUG DELIVERY OINTMENTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).................118
• TABLE 96
TOPICAL DRUG DELIVERY PASTES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)........................119
• TABLE 97
TOPICAL DRUG DELIVERY LOTIONS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)......................120
• TABLE 98
SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................120
• TABLE 99
SOLID TOPICAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................121
• TABLE 100
TOPICAL DRUG DELIVERY SUPPOSITORIES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..........121
• TABLE 101
TOPICAL DRUG DELIVERY POWDERS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)....................122
• TABLE 102
TRANSDERMAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................123
• TABLE 103
TRANSDERMAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)...................123
• TABLE 104
TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)......................................124
• TABLE 105
TRANSDERMAL GELS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).............................................124
• TABLE 106
IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................126
• TABLE 107
IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).....................127
• TABLE 108
ACTIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................127
• TABLE 109
PASSIVE IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................128
• TABLE 110
TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................130
• TABLE 111
TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................131
• TABLE 112
ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION)..............................................................................................................................131
• TABLE 113
ORAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................132
• TABLE 114
BUCCAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)..............132
sales@marketsandmarkets.com
www.marketsandmarkets.com
24
LIST OF TABLES
• TABLE 115
SUBLINGUAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)......................133
• TABLE 116
OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION).............................................................................................134
• TABLE 117
OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................................................................................................134
• TABLE 118
RECTAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................................................................................................135
• TABLE 119
VAGINAL TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).........................................................................................................136
• TABLE 120
DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION).........................139
• TABLE 121
DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013–2020 (USD BILLION).............................139
• TABLE 122
DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOSPITALS, BY REGION, 2013–2020 (USD BILLION)....................140
• TABLE 123
DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR HOME CARE SETTINGS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................141
• TABLE 124
DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR AMBULATORY SURGICAL CENTERS/CLINICS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................142
• TABLE 125
DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR DIAGNOSTIC CENTERS, BY REGION, 2013–2020 (USD BILLION).........................................................................................................143
• TABLE 126
DRUG DELIVERY TECHNOLOGY MARKET SIZE FOR OTHER END USERS, BY REGION, 2013–2020 (USD BILLION)..............................................................................................................................144
• TABLE 127
DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)..............................146
• TABLE 128
NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)..............................................................................................................................149
• TABLE 129
NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)...............................................................................................149
• TABLE 130
NORTH AMERICA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION)..............................................................................................................................150
• TABLE 131
U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)..............................................................................................................................151
• TABLE 132
U.S.: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION)...............................151
• TABLE 133
CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)..............................................................................................................................152
• TABLE 134
CANADA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION)........................153
• TABLE 135
EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)..............................................................................................................................156
sales@marketsandmarkets.com
www.marketsandmarkets.com
25
LIST OF TABLES
• TABLE 136
EUROPE: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION).........................156
• TABLE 137
ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)..............................................................................................................................159
• TABLE 138
ASIA: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION)...............159
• TABLE 139
ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2013–2020 (USD BILLION)..............................................................................................................................162
• TABLE 140
ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION)..............................162
• TABLE 141
NEW PRODUCT LAUNCHES & APPROVALS, 2012–2015...............................................................................167
• TABLE 142
PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS, 2012–2015.........................................................168
• TABLE 143
ACQUISITIONS, 2012–2015............................................................................................................................169
• TABLE 144
EXPANSIONS, 2012–2015...............................................................................................................................170
•
sales@marketsandmarkets.com
www.marketsandmarkets.com
26
LIST OF FIGURES
• FIGURE 1
RESEARCH DESIGN...........................................................................................................................................27
• FIGURE 2
MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH.....................................................................................29
• FIGURE 3
MARKET SIZE ESTIMATION: TOP-DOWN APPROACH......................................................................................29
• FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION.......................30
• FIGURE 5
DATA TRIANGULATION METHODOLOGY...........................................................................................................31
• FIGURE 6
DRUG DELIVERY TECHNOLOGY MARKET, BY ROUTE OF ADMINISTRATION (2015 VS. 2020)........................34
• FIGURE 7
ORAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2015 VS. 2020.....................................35
• FIGURE 8
HOSPITALS FORM THE LARGEST END-USER SEGMENT.................................................................................36
• FIGURE 9
TOPICAL DRUG DELIVERY TECHNOLOGY MARKET, BY DOSAGE FORM, 2015 VS. 2020................................36
• FIGURE 10
TOPICAL DRUG DELIVERY SEGMENT TO GROW AT THE HIGHEST CAGR FROM 2015 TO 2020.....................38
• FIGURE 11
HOSPITALS SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD...................................................39
• FIGURE 12
TABLETS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN 2015..........................................................40
• FIGURE 13
INJECTABLE DRUG DELIVERY TECHNOLOGY TO OFFER SIGNIFICANT CONTRIBUTION TO THE OVERALL MARKET GROWTH (2015-2020)...........................................................................................41
• FIGURE 14
ASIA TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD........................................................42
• FIGURE 15
DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION.......................44
• FIGURE 16
DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY END USER.....................................................45
• FIGURE 17
DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY REGION.........................................................45
• FIGURE 18
DRUG DELIVERY TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES.....................46
• FIGURE 19
TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD...............................59
• FIGURE 20
SOLID ORAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD.........................61
• FIGURE 21
NEBULIZERS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD....................................................72
• FIGURE 22
FORMULATIONS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD..............................................80
• FIGURE 23
LIQUID OCULAR DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD...................99
• FIGURE 24
NASAL SPRAYS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD..............................................108
• FIGURE 25
SEMI-SOLID TOPICAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD.......112
• FIGURE 26
PASSIVE IMPLANTABLE DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD....126
• FIGURE 27
ORAL TRANSMUCOSAL DRUG DELIVERY TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD.....130
• FIGURE 28
DRUG DELIVERY TECHNOLOGY MARKET SEGMENTATION, BY END USER...................................................138
• FIGURE 29
DRUG DELIVERY TECHNOLOGY MARKET, BY END USER: HOSPITALS TO HOLD LARGEST MARKET SHARE IN 2015................................................................................................................................................138
• sales@marketsandmarkets.com
www.marketsandmarkets.com
27
LIST OF FIGURES
• FIGURE 30
NORTH AMERICA TO HOLD THE LARGEST SHARE OF THE GLOBAL DRUG DELIVERY TECHNOLOGY MARKET (2015).......................................................................................................................148
• FIGURE 31
EUROPEAN DRUG DELIVERY TECHNOLOGY MARKET SNAPSHOT (2015)....................................................155
• FIGURE 32
ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE GLOBAL DRUG DELIVERY TECHNOLOGY MARKET (2015).......................................................................................................................158
• FIGURE 33
RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE DRUG DELIVERY TECHNOLOGY MARKET IN THE ROW (2015)..................................................................................................161
• FIGURE 34
NEW PRODUCT LAUNCHES & APPROVALS IS THE KEY GROWTH STRATEGY ADOPTED BY PLAYERS IN THE DRUG DELIVERY MARKET DURING THE STUDIED PERIOD (2014-2015).....................163
• FIGURE 35
GLOBAL DRUG DELIVERY TECHNOLOGY MARKET SHARE, BY KEY PLAYER (2014).....................................164
• FIGURE 36
MARKET EVOLUTION FRAMEWORK: NEW PRODUCT LAUNCHES & APPROVALS ARE FUELING MARKET GROWTH...........................................................................................................................................165
• FIGURE 37
BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES & APPROVALS IS THE KEY GROWTH STRATEGY ADOPTED BY LEADING PLAYERS IN 2015....................................................................166
• FIGURE 38
GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS.................................................................................171
• FIGURE 39
BAYER AG: COMPANY SNAPSHOT..................................................................................................................172
• FIGURE 40
JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT..................................................................175
• FIGURE 41
NOVARTIS AG: COMPANY SNAPSHOT...........................................................................................................182
• FIGURE 42
PFIZER, INC.: COMPANY SNAPSHOT..............................................................................................................186
• FIGURE 43
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT................................................................................196
• FIGURE 44
3M COMPANY: COMPANY SNAPSHOT...........................................................................................................204
• FIGURE 45
ANTARES PHARMA, INC: COMPANY SNAPSHOT...........................................................................................207
• FIGURE 46
GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT..........................................................................................209
• FIGURE 47
MERCK & CO., INC.: COMPANY SNAPSHOT..................................................................................................212
• FIGURE 48
SANOFI: COMPANY SNAPSHOT......................................................................................................................217
sales@marketsandmarkets.com
www.marketsandmarkets.com
28
SAMPLE TABLES
TABLE 1 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY DOSAGE FORM, 2013–2020 (USD BILLION) 2013
2014
2015
2020
CAGR (2015-2020)
Rectal
xx.x
xx.x
xx.x
xx.x
xx.x%
Vaginal
xx.x
xx.x
xx.x
xx.x
xx.x%
TOTAL
xx.x
xx.x
xx.x
xx.x
xx.x%
DOSAGE FORM
Source: Annual Reports, SEC Filings, Investor Presentations, Press Releases, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Ondrugdelivery.com, Center for Drug Delivery and Nanomedicine, National Center for Biotechnology Information, Expert Interviews, and MarketsandMarkets Analysis
TABLE 2 DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY REGION, 2013-2020 (USD BILLION) 2013
2014
2015
2020
CAGR (2015-2020)
North America
xx.x
xx.x
xx.x
xx.x
xx.x%
Europe
xx.x
xx.x
xx.x
xx.x
xx.x%
Asia
xx.x
xx.x
xx.x
xx.x
xx.x%
RoW
xx.x
xx.x
xx.x
xx.x
xx.x%
TOTAL
xx.x
xx.x
xx.x
xx.x
xx.x%
REGION
Source: Annual Reports, SEC Filings, Investor Presentations, Press Releases, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Ondrugdelivery.com, Center for Drug Delivery and Nanomedicine, National Center for Biotechnology Information, Expert Interviews, and MarketsandMarkets Analysis
TABLE 3 ROW: DRUG DELIVERY TECHNOLOGY MARKET SIZE, BY END USER, 2013–2020 (USD BILLION) 2013
2014
2015
2020
CAGR (2015-2020)
Hospitals
xx.x
xx.x
xx.x
xx.x
xx.x%
ASCs/Clinics
xx.x
xx.x
xx.x
xx.x
xx.x%
Home Care Settings
xx.x
xx.x
xx.x
xx.x
xx.x%
Diagnostic Centers
xx.x
xx.x
xx.x
xx.x
xx.x%
Other End Users
xx.x
xx.x
xx.x
xx.x
xx.x%
TOTAL
xx.x
xx.x
xx.x
xx.x
xx.x%
END USER
Source: Annual Reports, SEC Filings, Investor Presentations, Press Releases, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Ondrugdelivery.com, Center for Drug Delivery and Nanomedicine, National Center for Biotechnology Information, Expert Interviews, and MarketsandMarkets Analysis
sales@marketsandmarkets.com
www.marketsandmarkets.com
29
RELATED REPORTS
RELATED REPORTS SR. NO.
REPORT TITLE
PUBLISHED DATE
1
INJECTABLE DRUG DELIVERY MARKET by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home Care Setting) Global Forecast to 2020
2
EUROPEAN INJECTABLE DRUG DELIVERY MARKET by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) Forecast to 2020
sales@marketsandmarkets.com
www.marketsandmarkets.com
August 2015
July 2015
30
ABOUT MNM
MarketsandMarkets is a global market research and consulting company It is World’s No. 2 in terms of premium market research studies published annually. Serving as a business intelligence partner to Fortune 500 companies across the world, it provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers seventeen industry verticals, including advanced materials, aerospace and defense, agriculture, automotive and transportation, biotechnology, building and construction, chemicals, energy and power, food and beverages, industrial automation, medical devices, mining, minerals and metals, packaging, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.
Copyright © 2015 MarketsandMarkets All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
DISCLAIMER: MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation. MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets strategic analysis publications consist of the opinions of MarketsandMarkets’ research and should not be construed as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users. All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner. No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission. Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact: 1-888-600-6441 sales@marketsandmarkets.com
sales@marketsandmarkets.com
www.marketsandmarkets.com
31